Global-Spin News

Cambridge Enterprise Support Helps Spin-off Targets the Causes of Pulmonary Arterial Hypertension (PAH)

Cambridge Enterprise Support Helps Spin-off Targets the Causes of Pulmonary Arterial Hypertension (PAH)
Monday, 28 January 2019

Researchers at the University of Cambridge have access to additional help when setting up businesses with the support from Cambridge Enterprise, formed in 2006 with the intention to support the innovators and entrepreneurs from the school [1]. We can see the direct benefits of the investment made by the University in companies such as Morphogen-IX. Founded in 2015, Morphogen-IX is a company that focuses on the treatment of pulmonary arterial hypertension (PAH). [2]

PAH occurs when the small pulmonary arteries narrow, raising blood pressure within the heart (different from high blood pressure which is a much more general concern). It is considered to be a rare disease but mortality rates are still quite high, despite the currently available treatment. While there is much that we still need to understand, especially the genetic factors behind the disease, Morphogen-IX is a leader in its field and moving towards new solutions. [3]

And, at the end of 2018, Morphogen-IX announced that it has a candidate treatment for PAH called MGX292 and hopes to reach clinical trials by 2021. Whereas current therapy for this disease focuses on treating the damage, this new treatment has the potential to restore the system. [3] In order to reach this goal, the MGX292 carried out a round of Series B financing and raised £18.4M (approximately 20.315 million euros). This money will help support the team develop and clinically test the drug over the next few years. [4]

[1] https://www.enterprise.cam.ac.uk/who-we-are
[2] http://www.morphogen-ix.com
[3] https://pulmonaryhypertensionnews.com/2018/12/03/morphogen-ix-announces-mgx292-potential-pah-treatment-candidate
[4] https://endpts.com/targeting-underlying-cause-of-pah-cambridge-spinout-morphogen-ix-raises-about-23m-in-series-b